Neurobiological mechanisms in addictive and psychiatric disorders

Psychiatric Clinics of North America

Volumn 27, Issue 4, 2004, Pages 661-674

  Bruijnzeel, Adrie W ^a   Repetto, Martin ^a   Gold, Mark S ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Neuroscience Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2' METHOXYPHENYL) 1 [2' (2' PYRIDINYL) 4 IODOBENZAMIDO]ETHYLPIPERAZINE; ALCOHOL; AMPHETAMINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CANNABINOID; COCAINE; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; DEXAMETHASONE; DEXANABINOL; DIAZEPAM; DIMENHYDRINATE; DIPHENHYDRAMINE; FLUOXETINE; RIMONABANT; RITANSERIN; SEROTONIN 1A ANTAGONIST; UNCLASSIFIED DRUG;

ADDICTION; ANXIETY; BRAIN FUNCTION; COMORBIDITY; DEPRESSION; DRUG ABUSE; DRUG DEPENDENCE; DRUG USE; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENTAL DISEASE; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; WITHDRAWAL SYNDROME;

ANXIETY; BEHAVIOR, ADDICTIVE; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; ETHANOL; HUMANS; MENTAL DISORDERS; NARCOTICS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 8844254614     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2004.06.005     Document Type: Review

References (96)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 4th edition 1994 American Psychiatric Press Washington (DC)
2. G.F. Koob, and M. Le Moal Drug abuse: hedonic homeostatic dysregulation Science 278 1997 52 58
3. M.J. Kreek, and G.F. Koob Drug dependence: stress and dysregulation of brain reward pathways Drug Alcohol Depend 51 1998 23 47
4. A. Markou, T.R. Kosten, and G.F. Koob Neurobiological similarities in depression and drug dependence: a self-medication hypothesis Neuropsychopharmacology 18 1998 135 174
5. C.A. Dackis, and M.S. Gold New concepts in cocaine addiction: the dopamine depletion hypothesis Neurosci Biobehav Rev 9 1985 469 477
6. F. Weiss, R. Ciccocioppo, L.H. Parsons, S. Katner, X. Liu, and E.P. Zorrilla Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors Ann N Y Acad Sci 937 2001 1 26
7. M.S. Gold, and L.M. Tullis Cannabis M. Talanter H.D. Kleber Textbook of substance abuse treatment 2nd edition 2001 The American Psychiatric Press New York 165 181
8. R. Spanagel, and F. Weiss The dopamine hypothesis of reward: past and current status Trends Neurosci 22 1999 521 527
9. Z.L. Rossetti, Y. Hmaidan, and G.L. Gessa Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine, and amphetamine abstinence in rats Eur J Pharmacol 221 1992 227 234
10. Z. Sarnyai, Y. Shaham, and S.C. Heinrichs The role of corticotropin-releasing factor in drug addiction Pharmacol Rev 53 2001 209 243
11. G.F. Koob Stress, corticotropin-releasing factor, and drug addiction Ann N Y Acad Sci 897 1999 27 45
12. C. Dackis, and C. O'Brien Glutamatergic agents for cocaine dependence Ann N Y Acad Sci 1003 2003 328 345
13. F.H. Gawin, and H.D. Kleber Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations Arch Gen Psychiatry 43 1986 107 113
14. L. Semlitz, and M.S. Gold Adolescent drug abuse: diagnosis, treatment and prevention Psychiatr Clin North Am 9 3 1986 455 473
15. A.M. Washton, and M.S. Gold Recent trends in cocaine abuse: a view from the national hotline, "800 cocaine" Adv Alcohol Subst Abuse 6 2 1987 31 47
16. G.F. Koob Neuroadaptive mechanisms of addiction: studies on the extended amygdala Eur Neuropsychopharmacol 13 2003 442 452
17. A. Markou, and G.F. Koob Postcocaine anhedonia. An animal model of cocaine withdrawal Neuropsychopharmacology 4 1991 17 26
18. A. Markou, and G.F. Koob Bromocriptine reverses the elevation in intracranial self-stimulation thresholds observed in a rat model of cocaine withdrawal Neuropsychopharmacology 7 1992 213 224
19. B.A. Baldo, G.F. Koob, and A. Markou Role of adenosine A2 receptors in brain stimulation reward under baseline conditions and during cocaine withdrawal in rats J Neurosci 19 1999 11017 11026
20. M.S. Gold, and K. Verebey The psychopharmacology of cocaine Psychiatr Ann 14 10 1984 714 723
21. P.J. Kenny, I. Polis, G.F. Koob, and A. Markou Low-dose cocaine self-administration transiently increases, but high-dose cocaine persistently decreases brain reward function in rats Eur J Neurosci 17 2003 191 195
22. K.M. Kampman, A.I. Alterman, J.R. Volpicelli, I. Maany, E.S. Muller, and D.D. Luce Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment Psychol Addict Behav 15 2001 52 59
23. T.A. Paine, S.L. Jackman, and M.C. Olmstead Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydrinate, or diphenhydramine Behav Pharmacol 13 2002 511 523
24. X.M. Yang, A.L. Gorman, A.J. Dunn, and N.E. Goeders Anxiogenic effects of acute and chronic cocaine administration: neurochemical and behavioral studies Pharmacol Biochem Behav 41 1992 643 650
25. A.M. Basso, M. Spina, J. Rivier, W. Vale, and G.F. Koob Corticotropin-releasing factor antagonist attenuates the "anxiogenic- like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats Psychopharmacology (Berl) 145 1999 21 30
26. B. Costall, B.J. Jones, M.E. Kelly, R.J. Naylor, E.S. Onaivi, and M.B. Tyers Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse Pharmacol Biochem Behav 36 1990 339 344
27. D.J. Fontana, and R.L. Commissaris Effects of cocaine on conflict behavior in the rat Life Sci 45 1989 819 827
28. T.F. Meert Ritanserin overcomes exploratory inhibition induced by cocaine withdrawal Behav Pharmacol 3 1992 149 154
29. G.F. Koob, and S.C. Heinrichs A role for corticotropin releasing factor and urocortin in behavioral responses to stressors Brain Res 848 1999 141 152
30. P. Timpl, R. Spanagel, I. Sillaber, A. Kresse, J.M. Reul, and G.K. Stalla Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1 Nat Genet 19 1998 162 166
31. G.W. Smith, J.M. Aubry, F. Dellu, A. Contarino, L.M. Bilezikjian, and L.H. Gold Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development Neuron 20 1998 1093 1102
32. D.A. Gutman, M.J. Owens, K.H. Skelton, K.V. Thrivikraman, and C.B. Nemeroff The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress J Pharmacol Exp Ther 304 2003 874 880
33. L.W. Swanson, P.E. Sawchenko, J. Rivier, and W.W. Vale Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study Neuroendocrinology 36 1983 165 186
34. K. Van Pett, V. Viau, J.C. Bittencourt, R.K. Chan, H.Y. Li, and C. Arias Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse J Comp Neurol 428 2000 191 212
35. R.M. Richter, and F. Weiss In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats Synapse 32 1999 254 261
36. E.P. Zorrilla, G.R. Valdez, and F. Weiss Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats Psychopharmacology (Berl) 158 2001 374 381
37. Z. Sarnyai, E. Biro, J. Gardi, M. Vecsernyes, J. Julesz, and G. Telegdy Brain corticotropin-releasing factor mediates anxiety-like behavior induced by cocaine withdrawal in rats Brain Res 675 1995 89 97
38. L. Kokkinidis, R.M. Zacharko, and H. Anisman Amphetamine withdrawal: a behavioral evaluation Life Sci 38 1986 1617 1623
39. D. Lin, G.F. Koob, and A. Markou Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat - interactions between the two drugs Psychopharmacology (Berl) 145 1999 283 294
40. N.J. Leith, and R.J. Barrett Effects of chronic amphetamine or reserpine on self-stimulation responding: animal model of depression? Psychopharmacology (Berl) 72 1980 9 15
41. J.F. Cryan, D. Hoyer, and A. Markou Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents Biol Psychiatry 54 2003 49 58
42. J.F. Cryan, A. Markou, and I. Lucki Assessing antidepressant activity in rodents: recent developments and future needs Trends Pharmacol Sci 23 2002 238 245
43. A.M. Barr, A. Markou, and A.G. Phillips A 'crash' course on psychostimulant withdrawal as a model of depression Trends Pharmacol Sci 23 2002 475 482
44. A.A. Harrison, Y.T. Liem, and A. Markou Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats Neuropsychopharmacology 25 2001 55 71
45. P. Blier The pharmacology of putative early-onset antidepressant strategies Eur Neuropsychopharmacol 13 2003 57 66
46. H.C. Becker Animal models of alcohol withdrawal Alcohol Res Health 24 2000 105 113
47. D.J. Macey, G. Schulteis, S.C. Heinrichs, and G.F. Koob Time-dependent quantifiable withdrawal from ethanol in the rat: effect of method of dependence induction Alcohol 13 1996 163 170
48. S.E. File, H.A. Baldwin, and P.K. Hitchcott Flumazenil but not nitrendipine reverses the increased anxiety during ethanol withdrawal in the rat Psychopharmacology (Berl) 98 1989 262 264
49. S.E. File, A. Zharkovsky, and K. Gulati Effects of baclofen and nitrendipine on ethanol withdrawal responses in the rat Neuropharmacology 30 1991 183 190
50. M.F. Mayo-Smith Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal JAMA 278 1997 144 151
51. W. Hall, and D. Zador The alcohol withdrawal syndrome Lancet 349 1997 1897 1900
52. P.E. Merlo, M. Lorang, M. Yeganeh, D.F. Rodriguez, J. Raber, and G.F. Koob Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis J Neurosci 15 1995 5439 5447
53. H.A. Baldwin, S. Rassnick, J. Rivier, G.F. Koob, and K.T. Britton CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat Psychopharmacology (Berl) 103 1991 227 232
54. S. Rassnick, S.C. Heinrichs, K.T. Britton, and G.F. Koob Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal Brain Res 605 1993 25 32
55. D.L. Walker, D.J. Toufexis, and M. Davis Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety Eur J Pharmacol 463 2003 199 216
56. M.F. Olive, H.N. Koenig, M.A. Nannini, and C.W. Hodge Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake Pharmacol Biochem Behav 72 2002 213 220
57. G. Schulteis, A. Markou, M. Cole, and G.F. Koob Decreased brain reward produced by ethanol withdrawal Proc Natl Acad Sci U S A 92 1995 5880 5884
58. M. Haney, A.S. Ward, S.D. Comer, R.W. Foltin, and M.W. Fischman Abstinence symptoms following oral THC administration to humans Psychopharmacology (Berl) 141 1999 385 394
59. M. Haney, A.S. Ward, S.D. Comer, R.W. Foltin, and M.W. Fischman Abstinence symptoms following smoked marijuana in humans Psychopharmacology (Berl) 141 1999 395 404
60. E.M. Kouri, H.G. Pope Jr., and S.E. Lukas Changes in aggressive behavior during withdrawal from long-term marijuana use Psychopharmacology (Berl) 143 1999 302 308
61. M.P. Naditch Acute adverse reactions to psychoactive drugs, drug usage, and psychopathology J Abnorm Psychol 83 1974 394 403
62. M.D. Aceto, S.M. Scates, J.A. Lowe, and B.R. Martin Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal J Pharmacol Exp Ther 278 1996 1290 1295
63. D.F. Rodriguez, M.R. Carrera, M. Navarro, G.F. Koob, and F. Weiss Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal Science 276 1997 2050 2054
64. R.C. Kessler, K.A. McGonagle, S. Zhao, C.B. Nelson, M. Hughes, and S. Eshleman Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey Arch Gen Psychiatry 51 1994 8 19
65. H. Selye A syndrome produced by diverse noxious agents Nature 138 1936 32 39
66. N. Sonino, and G.A. Fava Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology, and treatment CNS Drugs 15 2001 361 373
67. F. Board, R. Wadeson, and H. Persky Depressive affect and endocrine functions; blood levels of adrenal cortex and thyroid hormones in patients suffering from depressive reactions AMA Arch Neurol Psychiatry 78 1957 612 620
68. B.J. Carroll, M. Feinberg, J.F. Greden, J. Tarika, A.A. Albala, and R.F. Haskett A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility Arch Gen Psychiatry 38 1981 15 22
69. P.W. Gold, G. Chrousos, C. Kellner, R. Post, A. Roy, and P. Augerinos Psychiatric implications of Go and ld basic clinical studies with corticotropin-releasing factor Am J Psychiatry 141 1984 619 627
70. D.A. Gutman, and C.B. Nemeroff Persistent central nervous system effects of an adverse early environment: clinical and preclinical studies Physiol Behav 79 2003 471 478
71. C. Heim, and C.B. Nemeroff The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders Biol Psychiatry 46 1999 1509 1522
72. F. Holsboer The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety J Psychiatr Res 33 1999 181 214
73. C.B. Nemeroff, E. Widerlov, G. Bissette, H. Walleus, I. Karlsson, and K. Eklund Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients Science 226 1984 1342 1344
74. M. Arato, C.M. Banki, C.B. Nemeroff, and G. Bissette Hypothalamic- pituitary-adrenal axis and suicide Ann N Y Acad Sci 487 1986 263 270
75. C.M. Banki, G. Bissette, M. Arato, L. O'Connor, and C.B. Nemeroff CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia Am J Psychiatry 144 1987 873 877
76. C.M. Banki, L. Karmacsi, G. Bissette, and C.B. Nemeroff Cerebrospinal fluid neuropeptides in mood disorder and dementia J Affect Disord 25 1992 39 45
77. R.D. France, B. Urban, K.R. Krishnan, G. Bissett, C.M. Banki, and C. Nemeroff CSF corticotropin-releasing factor-like immunoactivity in chronic pain patients with and without major depression Biol Psychiatry 23 1988 86 88
78. S.C. Risch, R.J. Lewine, R.D. Jewart, W.E. Pollard, J.M. Caudle, and N.H. Kalin Relationship between cerebrospinal fluid peptides and neurotransmitters in depression S.C. Risch Central nervous system peptide mechanisms in stress and depression 1991 American Psychiatric Press Washington (DC) 93 103
79. C.B. Nemeroff, G. Bissette, H. Akil, and M. Fink Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin Br J Psychiatry 158 1991 59 63
80. R.C. Veith, N. Lewis, J.I. Langohr, M.M. Murburg, E.A. Ashleigh, and S. Castillo Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects Psychiatry Res 46 1993 1 8
81. M.D. De Bellis, P.W. Gold, T.D. Geracioti Jr., S.J. Listwak, and M.A. Kling Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression Am J Psychiatry 150 1993 656 657
82. M. Altemus, T. Pigott, K.T. Kalogeras, M. Demitrack, B. Dubbert, and D.L. Murphy Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder Arch Gen Psychiatry 49 1992 9 20
83. M. Altemus, S.E. Swedo, H.L. Leonard, D. Richter, D.R. Rubinow, and W.Z. Potter Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine Arch Gen Psychiatry 51 1994 794 803
84. J.D. Bremner, J. Licinio, A. Darnell, J.H. Krystal, M.J. Owens, and S.M. Southwick Elevated CSF corticotropin-releasing factor concentrations in post-traumatic stress disorder Am J Psychiatry 154 1997 624 629
85. K.J. Ressler, and C.B. Nemeroff Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders Depress Anxiety 12 Suppl 1 2000 2 19
86. J.F. Lopez, D.T. Chalmers, K.Y. Little, and S.J. Watson Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression Biol Psychiatry 43 1998 547 573
87. N.S. Miller, D. Klamen, N.G. Hoffmann, and J.A. Flaherty Prevalence of depression and alcohol and other drug dependence in addictions treatment populations J Psychoactive Drugs 28 1996 111 124
88. M.A. Schuckit, J.E. Tipp, M. Bergman, W. Reich, V.M. Hesselbrock, and T.L. Smith Comparison of induced and independent major depressive disorders in 2945 alcoholics Am J Psychiatry 154 1997 948 957
89. D.A. Regier, M.E. Farmer, D.S. Rae, B.Z. Locke, S.J. Keith, and L.L. Judd Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study JAMA 264 1990 2511 2518
90. R.C. Kessler, C.B. Nelson, K.A. McGonagle, M.J. Edlund, R.G. Frank, and P.J. Leaf The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization Am J Orthopsychiatry 66 1996 17 31
91. A. Roy, J. DeJong, D. Lamparski, T. George, and M. Linnoila Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables Arch Gen Psychiatry 48 1991 428 432
92. M.A. Schuckit The clinical implications of primary diagnostic groups among alcoholics Arch Gen Psychiatry 42 1985 1043 1049
93. D.P. Devanand Comorbid psychiatric disorders in late life depression Biol Psychiatry 52 2002 236 242
94. J.M. Rey, M.G. Sawyer, B. Raphael, G.C. Patton, and M. Lynskey Mental health of teenagers who use cannabis. Results of an Australian survey Br J Psychiatry 180 2002 216 221
95. R. McGee, S. Williams, R. Poulton, and T. Moffitt A longitudinal study of cannabis use and mental health from adolescence to early adulthood Addiction 95 2000 491 503
96. M.S. Gold, and N.S. Miller The biology of addictive and psychiatric disorders N.S. Miller Treating Coexisting Psychiatric and Addictive Disorders 1994 Hazelden Center City, MN 35 52